From theheart.org on Medscape

Coverage from the

American College of Cardiology (ACC) 2017 Scientific Sessions

March 17 - 19, 2017; Washington, DC

March 17 - 19, 2017 Washington, DC

ACC High Troponin-T After Noncardiac Surgery May Predict Mortality In VISION, 93% of the myocardial injury after noncardiac surgery would have "likely gone undetected" without troponin monitoring because of no symptoms of ischemia.
Heartwire from Medscape, March 24, 2017
ACC Rivaroxaban Doesn't Increase Post-ACS Bleeding vs Aspirin: Study In GEMINI-ACS-1, bleeding risk did not differ significantly between patients on a P2Y12 inhibitor plus rivaroxaban vs aspirin. But is it really time to throw out aspirin as "the cornerstone" of ACS treatment?
Heartwire from Medscape, March 19, 2017
ACC Evolocumab Added to Statins Cuts CV Events in FOURIER Trial UPDATED // In the heavily anticipated FOURIER outcomes trial, the PCSK9 inhibitor met its primary and key secondary measures. But is it enough to shut down concerns over costs for the medication class?
Heartwire from Medscape, March 17, 2017

Meeting Highlights At A Glance

Top News From ACC 2017: Slideshow Highly anticipated data on PCSK9 inhibitors were featured prominently at this year's scientific sessions.

Conference News

ACC Silent Cerebral Microbleeds Common After TAVR, Says Study
Heartwire from Medscape, April 17, 2017
ACC Older Men on PDE-5 Inhibitors After MI: Reduced Death, HF Risk
Heartwire from Medscape, April 4, 2017
ACC MRI Helps Screen Teens for SCD Risk at Exercise, but Should It?
Heartwire from Medscape, March 31, 2017
ACC LAA Closure at Surgery Reduces Embolic Risk in AF: STS Registry
Heartwire from Medscape, March 31, 2017
ACC HbA1c Fell in Diabetics on Sacubitril/Valsartan: PARADIGM-HF
Heartwire from Medscape, March 30, 2017
ACC 'Closed-Loop Stimulation' Pacing May Relieve Recurrent Syncope
Heartwire from Medscape, March 29, 2017
ACC Fewer Bleeds on Uninterrupted Dabigatran vs Warfarin in AF Ablation
Heartwire from Medscape, March 28, 2017
ACC No Plaque Reduction Seen With Mimetic HDL Agent in ACS
Heartwire from Medscape, March 27, 2017
ACC Valve-in-Valve TAVR as Safe as Native-Valve TAVR: Registry
Heartwire from Medscape, March 27, 2017
ACC Impella Pump Takes Positive Turn in Cardiogenic Shock Study
Heartwire from Medscape, March 27, 2017
ACC Spironolactone Promising in Duchenne Muscular Dystrophy
Medscape Medical News, March 24, 2017
ACC High Troponin-T After Noncardiac Surgery May Predict Mortality
Heartwire from Medscape, March 24, 2017
ACC Embolic 'Protection' at SAVR: Data Disappoint but Optimism Reigns
March 24, 2017
ACC 'Suggestion' of Brain Changes on Statins by fMRI in STOMP
Heartwire from Medscape, March 23, 2017
ACC MitraClip Issues, Outcomes in US Registry Experience
Heartwire from Medscape, March 23, 2017
ACC HF, Survival Gains on SGLT-2 Inhibitors: Real-world Experience
Heartwire from Medscape, March 23, 2017
ACC LEVO-CTS: No Levosimendan Protection at Low-EF Cardiac Surgery
Heartwire from Medscape, March 22, 2017

ACC Meds Sans PCI Judged OK for CTO in Trial, Methods Questioned
Heartwire from Medscape, March 22, 2017
ACC Higher Leaflet Thrombosis Risk With TAVR, DAPT Not Protective
Heartwire from Medscape, March 21, 2017
ACC No Cognitive Impairment on Evolocumab in EBBINGHAUS Study
Heartwire from Medscape, March 21, 2017
ACC PCSK9 Inhibitor Access Snarled in Red Tape, Rejections
Heartwire from Medscape, March 21, 2017
ACC Fewer HF Hospitalizations With CardioMEMS-Guided Management
Heartwire from Medscape, March 20, 2017
ACC Clinical Outcomes Trials Put iFR in Same League With FFR
Heartwire from Medscape, March 19, 2017
ACC ABSORB-3 at 2 Years: More CV Events With Absorb BVS vs Xience
Heartwire from Medscape, March 19, 2017
ACC Rivaroxaban Doesn't Increase Post-ACS Bleeding vs Aspirin: Study
Heartwire from Medscape, March 19, 2017
ACC Fewer Re-PCIs After Primary PCI Plus FFR-Guided Intervention
Heartwire from Medscape, March 19, 2017
ACC EINSTEIN CHOICE: Rivaroxaban Beats Aspirin for VTE Recurrence
Heartwire from Medscape, March 18, 2017
ACC LDL-C Plunges on Novel Anti-PCSK9 Agent Inclisiran: ORION-1
Heartwire from Medscape, March 18, 2017
ACC Brisk Walking Can Help in Hypertrophic Cardiomyopathy
Heartwire from Medscape, March 18, 2017
Alert ACC FDA Warns of CV Event Risk With Absorb BVS
News Alerts, March 18, 2017
ACC SPIRE Trials: Immune Response Thwarts PCSK9 Inhibitor Bococizumab
Heartwire from Medscape, March 17, 2017
ACC SURTAVI: TAVR, SAVR Stand Toe-to-Toe in Intermediate-Risk Patients
Heartwire from Medscape, March 17, 2017
ACC Evolocumab Added to Statins Cuts CV Events in FOURIER Trial
Heartwire from Medscape, March 17, 2017
ACC PCSK9 at ACC Sessions Joins Washington, DC, Acronym Alphabet Soup
Heartwire from Medscape, March 14, 2017

Popular News from ACC 2016

HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients UPDATED // Alone or with blood-pressure-lowering therapy, at least in those with elevated baseline BP, rosuvastatin lowered composite end points by 24% to 29% vs placebo.
Medscape Medical News, Apr 2, 2016
GAUSS-3: Evolocumab Cuts LDL-C in Statin-Intolerant Patients UPDATED // "We have established that you can use PCSK9 inhibitors successfully" in this patient population, said the lead author. "And that has regulatory and practice implications."
Medscape Medical News, Apr 3, 2016
Shared Decision Making in Low-Risk Chest Pain: Safe, Fewer Tests While most shared decision-making tools "just end up sitting on shelves," the Chest Pain Choice aid used in the emergency department had clinical acceptability, an expert said.
Medscape Medical News, Apr 7, 2016

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives from ACC

Behind the Scenes of a First Presentation at a Major Meeting
Presenter: Sheila Sahni, MD;
Interviewer: Melissa Walton-Shirley;
Editor: Tricia Ward; Video Editors: Peter Zunitch and Mary Foti
Roadmap for a First Presentation at a Major Meeting
Interviewer: Melissa Walton-Shirley, MD; Interviewee: Sheila Sahni MD
Long Life vs Living Well: AHA Addresses Elderly With CVD
Ileana L. Piña, MD, MPH; Daniel E. Forman, MD
Arts and Medicine: An Interview With the Smithsonian Secretary
Tricia Ward; David J. Skorton, MD
Predicting Mortality Risk: Role of New Troponin Assay
Arefa Cassoobhoy, MD, MPH;
Melissa Walton-Shirley, MD
FOURIER: How Low Should LDL Go?
Arefa Cassoobhoy, MD, MPH;
Melissa Walton-Shirley, MD
How Sherlock Holmes Could Restore Faith in Science
Tricia Ward; David J. Skorton, MD
Digoxin: ARISTOTLE Substudy Provides Clues to a Threshold for This Last-Resort Drug
Ileana L. Piña, MD, MPH; Gaetano M. De Ferrari, MD
Implications of Subclinical Leaflet Thrombosis in TAVR/SAVR
John M. Mandrola, MD;
Raj R. Makkar, MD
FOURIER Presenter, Dr Marc Sabatine, Interviewed
nterviewer: John M. Mandrola, MD;
Interviewee: Marc S. Sabatine, MD, MPH
Alt FOURIER: Diet and Exercise vs PCSK9i?
Melissa Walton-Shirley, MD;
John M. Mandrola, MD
FOURIER/EBBINGHAUS: So Far, So Good. But Can We Afford It?
Robert A. Harrington, MD;
Clyde W. Yancy, MD, MSc

Bloggers from the Floor

Small Clots in Bioprosthetic Valves Should Slow TAVR Train Dr John Mandrola summarizes the findings of a study of the RESOLVE and SAVORY registries on subclinical thrombosis in surgical and transcatheter valve replacement.
First Clinical Trial of CTO Procedures Fails to Deliver Given the rise of procedures for chronic total coronary occlusions, Dr. Mandrola feels that the decidedly negative DECISION-CTO trial is the most important study from the second day of ACC.
Ten Quick Thoughts on FOURIER Dr Mandrola attended the late-breaking session at ACC and has these 10 quick thoughts on the landmark FOURIER trial.

Harnessing Nature to Prevent CVD: Practice Takeaways, Part 2 Dr Melissa Walton-Shirley continues her sum-up of a session dedicated to genetics and cardiovascular disease.
Harnessing Nature to Prevent CVD: Practice Takeaways, Part 1 Dr Melissa Walton-Shirley provides a precis of talks given on a session dedicated to genetics and cardiovascular disease.
What I'll Tell My Patients About FOURIER, SPIRE, and SURTAVI Dr Melissa Walton-Shirley recaps the three late-breakers from day 1 at ACC in patient-friendly language.
#ACC17 Best Meeting in Years: Here's Why Dr Melissa Walton-Shirley summarizes what was great about the ACC meeting this year, including some high points in presentations.

Pre-meeting Perspective

Mandrola Previews ACC 2017
John M. Mandrola, MD
Should Cost of Therapy Be Considered in Cardiovascular Guidelines?
Michelle L. O'Donoghue, MD, MPH

Previous Coverage